Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) and Oncolytics Biotech (NASDAQ:ONCY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Valuation and Earnings
This table compares Jazz Pharmaceuticals PLC and Oncolytics Biotech’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Jazz Pharmaceuticals PLC||$1.54 billion||5.51||$758.97 million||$6.45||21.92|
Jazz Pharmaceuticals PLC has higher revenue and earnings than Oncolytics Biotech.
Insider and Institutional Ownership
88.3% of Jazz Pharmaceuticals PLC shares are owned by institutional investors. 4.3% of Jazz Pharmaceuticals PLC shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
This is a breakdown of current ratings and price targets for Jazz Pharmaceuticals PLC and Oncolytics Biotech, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jazz Pharmaceuticals PLC||0||5||15||0||2.75|
Jazz Pharmaceuticals PLC presently has a consensus price target of $181.20, suggesting a potential upside of 28.17%. Given Jazz Pharmaceuticals PLC’s higher possible upside, research analysts clearly believe Jazz Pharmaceuticals PLC is more favorable than Oncolytics Biotech.
This table compares Jazz Pharmaceuticals PLC and Oncolytics Biotech’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jazz Pharmaceuticals PLC||25.69%||22.75%||9.14%|
Jazz Pharmaceuticals PLC beats Oncolytics Biotech on 8 of the 9 factors compared between the two stocks.
Jazz Pharmaceuticals PLC Company Profile
Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder. Its marketed products and late-stage product candidate are Xyrem (sodium oxybate) oral solution, Luvox CR (fluvoxamine maleate) Extended-Release Capsules and JZP-6 (sodium oxybate). Its other product candidates in clinical development are oral tablet forms of sodium oxybate; JZP-8 (intranasal clonazepam); JZP-4 (elpetrigine), and JZP-7 (ropinirole gel).
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc. is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials. The Company focuses on the registration of REOLYSIN in approximately two indications, including the neoadjuvant treatment of muscle-invasive bladder cancer and the treatment of glioblastoma. The Company has conducted a single arm United States Phase II non-small cell lung cancer (NSCLC) trial and a single arm United States Phase II pancreatic cancer trial for REOLYSIN. The Company is also engaged in conducting a Phase Ib trial for REOLYSIN and chemotherapy in combination with pembrolizumab in its Checkpoint Inhibitor Program.
Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.